Project Grant R37CA287204
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$1.9M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) totaling $1,295,508 to The Washington University in St. Louis to research novel chemical inhibitors of the NRF2 transcription factor as combination agents with radiation therapy (RT) for head and neck squamous cell carcinoma (HNSCC). The key objectives are to evaluate the efficacy and toxicity of two NRF2 inhibitors, VVD065 and WCDD115, when combined with RT in HNSCC xenograft, syngeneic, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,304,828 to The Washington University in St. Louis to conduct a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The research aims to assess the cytotoxic and immunomodulatory effects of (R)-9B, a small molecule that inhibits the ACK1...
This Project Grant award, totaling $393,943, was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Washington University located in St. Louis, Missouri. The award supports research to define the cellular and biochemical mechanisms that can be exploited to improve the efficacy and toxicity profile of PARP inhibitor (PARPi) therapy for BRCA-mutant cancers. Key objectives include: Determining how loss of the chromatin remodeling enzyme ALC1...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
The National Cancer Institute awarded a $600,079 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to develop novel high linear energy transfer (high-LET) molecular radiotherapies for relapsed and refractory neuroblastoma, the most common extracranial solid cancer in children. The project aims to evaluate the efficacy, tumor control, and cellular/genomic effects of combination treatments using the high-LET radiopharmaceuticals 77Br-MBBG (Auger...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $703,540.00 to Brigham & Women's Hospital Inc. to develop and optimize highly effective treatments for head and neck cancer using in situ implantable microdevices. The primary goals are to: Conduct a clinical study to validate the performance of the microdevice in predicting patients' clinical response to immunotherapy and chemotherapy for head and neck squamous cell...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $662,096 Project Grant to the Beckman Research Institute of the City of Hope in California. The grant, awarded on February 1, 2025, will fund a 5-year research project to investigate the use of the mitochondrial inhibitor papaverine in combination with short-course radiation therapy to enhance tumor radiosensitization and improve treatment outcomes for patients with locally...